Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05406232 · ClinicalTrials.gov registry record
Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
A clinical trial of Breast Carcinoma and Invasive Breast Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 12
- Enrollment target
- 1
- Study location
NCT05406232 is a study of Breast Carcinoma and Invasive Breast Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 12 participants, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05406232, a study of Breast Carcinoma and Invasive Breast Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This study assesses changes to the immune cells following hypofractionated radiation-induced DNA damage in breast cancer patients. Radiation therapy may cause immune cells to enter tumors and target cancer cells. The goal of this study is to measure the change in the level of immune cells in the tumor before and after radiation therapy.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Biopsy
- RADIATION Radiation Therapy
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-09-15 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05406232
The ClinicalTrials.gov registry entry for NCT05406232 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (98% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Biospecimen Collection is the first listed.
NCT05406232 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05406232 about?
NCT05406232 is a clinical study titled "Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer". This study assesses changes to the immune cells following hypofractionated radiation-induced DNA damage in breast cancer patients. Radiation therapy may cause immune cells to enter tumors and target cancer cells. The goal of this study is to measure the change in the level of immune cells in the tum...
What is the current status of trial NCT05406232?
This trial is currently recruiting. The enrollment target is 12 participants. The study started on 2023-09-15. Estimated completion is 2026-12-31.
What conditions does trial NCT05406232 study?
This clinical trial studies the following conditions: Breast Carcinoma, Invasive Breast Carcinoma.
What interventions are being tested in trial NCT05406232?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Biopsy (PROCEDURE), Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT05406232?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05406232 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Surviving Daily Life
RECRUITING
-
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
RECRUITING
-
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
RECRUITING · Phase 2
-
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
RECRUITING · Phase 2
-
Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer
RECRUITING
-
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.